Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: February 2013

34 - Pharmacotherapyof emotional disturbances

from Section III - Treatments in Behavioral Neurology & Neuropsychiatry

Summary

Forensic practice is a peculiar niche of medicine, often requiring a different approach and thought process than that routinely utilized in clinical practice. The forensic evaluator must inform the subject under examination of the exact nature and purpose of the evaluation, and make clear that a typical doctor-patient relationship is not being established. Competency is a broad area of forensic practice, with important applications to routine clinical medicine as well as criminal and civil law. Competency to proceed to trial is a major source of forensic psychiatric evaluations. Tort law covers an expansive range of legal issues, only some of which are likely to involve the use of neuropsychiatric experts. The neuropsychiatrist who accepts a forensic role also assumes tremendous responsibilities involving up-to-date medical knowledge, familiarity with pertinent law, and ethical duties particular to the medical expert role.

References

1. DubovskySL, DubovskyAN.Concise Guide to Mood Disorders. 1st edition. Washington, DC: American Psychiatric Publishing; 2002.
2. American Psychiatric Association Task Force on DSM–IV. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision: DSM–IV–TR. Washington, DC: American Psychiatric Association; 2000.
3. CookKF, BombardierCH, BamerAMet al. Do somatic and cognitive symptoms of traumatic brain injury confound depression screening?Arch Phys Med Rehabil. 2011;92(5):818–23.
4. BombardierCH, FannJR, TemkinNRet al. Rates of major depressive disorder and clinical outcomes following traumatic brain injury. J Am Med Assoc 2010;303(19):1938–45.
5. FannJR, UomotoJM, KatonWJ.Sertraline in the treatment of major depression following mild traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2000;12(2):226–32.
6. FannJR, UomotoJM, KatonWJ.Cognitive improvement with treatment of depression following mild traumatic brain injury. Psychosomatics 2001;42(1):48–54.
7. CummingTB, ChurilovL, SkoogI, BlomstrandC, LindenT.Little evidence for different phenomenology in poststroke depression. Acta Psychiatr Scand. 2010;121(6):424–30.
8. SpallettaG, RobinsonRG.How should depression be diagnosed in patients with stroke? Acta Psychiatr Scand. 2010;121(6):401–3.
9. ArciniegasDB.New-onset bipolar disorder in late life: a case of mistaken identity. Am J Psychiatry 2006;163(2):198–203.
10. CardnoAG, MarshallEJ, CoidBet al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry 1999;56(2):162–8.
11. KendlerKS, PedersenNL, NealeMC, MatheAA.A pilot Swedish twin study of affective illness including hospital- and population-ascertained subsamples: results of model fitting. Behav Genet. 1995;25(3):217–32.
12. KieseppaT, PartonenT, HaukkaJ, KaprioJ, LonnqvistJ.High concordance of bipolar I disorder in a nationwide sample of twins. Am J Psychiatry 2004;161(10):1814–21.
13. HenryC, Van den BulkeD, BellivierFet al. Affective lability and affect intensity as core dimensions of bipolar disorders during euthymic period. Psychiatry Res. 2008;159(1–2):1–6.
14. RamasubbuR, KennedySH.Factors complicating the diagnosis of depression in cerebrovascular disease, Part II – Neurological deficits and various assessment methods. Can J Psychiatry 1994;39(10):601–7.
15. RossED.The aprosodias. Functional-anatomic organization of the affective components of language in the right hemisphere. Arch Neurol. 1981;38(9):561–9.
16. DubovskySL.Using electroconvulsive therapy for patients with neurological disease. Hosp Community Psychiatry 1986;37(8):819–25.
17. KannerAM.Should neurologists be trained to recognize and treat comorbid depression of neurologic disorders? Yes. Epilepsy Behav. 2005;6:303–11.
18. NilssonFM, KessingLV, SorensenTM, AndersenPK, BolwigTG.Affective disorders in neurological diseases: a case register-based study. Acta Psychiatr Scand. 2003;108(1):41–50.
19. TaylorL, WicksP, LeighPN, GoldsteinLH.Prevalence of depression in amyotrophic lateral sclerosis and other motor disorders. Eur J Neurol. 2010;17(8):1047–53.
20. AtassiN, CookA, PinedaCMet al. Depression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12(2):109–12.
21. PattenSB, BerzinsS, MetzLM.Challenges in screening for depression in multiple sclerosis. Mult Scler. 2010;16(11):1406–11.
22. StarksteinSE, DragovicM, JorgeR, BrockmanS, RobinsonRG.Diagnostic criteria for depression in Alzheimer disease: a study of symptom patterns using latent class analysis. Am J Geriatr Psychiatry 2011;19(6):551–8.
23. MarshL, McDonaldWM, CummingsJ, RavinaB.Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord. 2006;21(2):148–58.
24. OttmanR, LiptonRB, EttingerABet al. Comorbidities of epilepsy: results from the Epilepsy Comorbidities and Health (EPIC) survey. Epilepsia 2011;52(2):308–15.
25. BlassDM, RabinsPV.Depression in frontotemporal dementia. Psychosomatics 2009;50(3):239–47.
26. DubovskySL, DubovskyAN.Geriatric neuropsychopharmacology. In CoffeyCE, CummingsJL, editors. The American Psychiatric Press Textbook of Geriatric Neuropsychiatry. 3rd edition. Washington, DC: American Psychiatric Press; 2010.
27. AarslandD, BronnickK, AlvesGet al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80(8):928–30.
28. KozoraE, ArciniegasDB, FilleyCMet al. Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. Arthritis Rheum. 2008;59(11):1639–46.
29. HarelL, SandborgC, LeeT, von SchevenE.Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol. 2003;33(9):1873–7.
30. KulaksizogluIB.Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs 2007;21(6):473–81.
31. GreimB, EngelC, ApelA, ZettlUK.Fatigue in neuroimmunological diseases. J Neurol. 2007;254(Suppl. 2):II102–6.
32. HenriquezSA, BrettR, AlexanderJ, PrattJ, RobertsCW.Neuropsychiatric disease and Toxoplasma gondii infection. Neuroimmunomodulation. 2009;16(2):122–33.
33. BerthierML, KulisevskyJ, GironellA, Fernandez BenitezJA.Poststroke bipolar affective disorder: clinical subtypes, concurrent movement disorders, and anatomical correlates. J Neuropsychiatry Clin Neurosci. 1996;8(2):160–7.
34. StarksteinSE, MaybergHS, BerthierMLet al. Mania after brain injury: neuroradiological and metabolic findings. Ann Neurol. 1990;27(6):652–9.
35. StarksteinSE, RobinsonRG.Mood disorders in neurodegenerative diseases. Semin Clin Neuropsychiatry 1996;1(4):272–81.
36. StarksteinSE, RobinsonRG.Mechanism of disinhibition after brain lesions. J Nerv Ment Dis. 1997;185(2):108–14.
37. OsterTJ, AndersonCA, FilleyCM, WortzelHS, ArciniegasDB.Quetiapine for mania due to traumatic brain injury. CNS Spectr. 2007;12(10):764–9.
38. ShulmanKI, TohenM, SatlinA, MallyaG, KalunianD.Mania compared with unipolar depression in old age. Am J Psychiatry 1992;149(3):341–5.
39. WortzelHS, OsterTJ, AndersonCA, ArciniegasDB.Pathological laughing and crying: epidemiology, pathophysiology and treatment. CNS Drugs 2008;22(7):531–45.
40. ParviziJ, AndersonSW, MartinCO, DamasioH, DamasioAR.Pathological laughter and crying: a link to the cerebellum. Brain 2001;124(Pt 9):1708–19.
41. ArciniegasDB, TopkoffJ.The neuropsychiatry of pathologic affect: an approach to evaluation and treatment. Semin Clin Neuropsychiatry 2000;5(4):290–306.
42. WilsonSA.Original papers: some problems in neurology. J Neurol Psychopathol. 1924;4(16):299–333.
43. SchifferRB, HerndonRM, RudickRA.Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med. 1985;312(23):1480–2.
44. CummingsJL, ArciniegasDB, BrooksBRet al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr. 2006;11(6):1–7.
45. ParviziJ, ArciniegasDB, BernardiniGLet al. Diagnosis and management of pathological laughter and crying. Mayo Clin Proc. 2006;81(11):1482–6.
46. BrooksBR.Involuntary emotional expression disorder: treating the untreated. CNS Spectr. 2007;12(4 Suppl. 5):23–7.
47. CalvertT, KnappP, HouseA.Psychological associations with emotionalism after stroke. J Neurol Neurosurg Psychiatry 1998;65(6):928–9.
48. RabinsPV, ArciniegasDB.Pathophysiology of involuntary emotional expression disorder. CNS Spectr. 2007;12(4 Suppl. 5):17–22.
49. HouseA, DennisM, MolyneuxA, WarlowC, HawtonK.Emotionalism after stroke. Br Med J. 1989;298(6679):991–4.
50. KimJS.Pathological laughter and crying in unilateral stroke. Stroke 1997;28(11):2321.
51. RobinsonRG, ParikhRM, LipseyJR, StarksteinSE, PriceTR.Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993;150(2):286–93.
52. ZeiligG, DrubachDA, Katz-ZeiligM, KaratinosJ.Pathological laughter and crying in patients with closed traumatic brain injury. Brain Inj. 1996;10(8):591–7.
53. TatenoA, JorgeRE, RobinsonRG.Pathological laughing and crying following traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2004;16(4):426–34.
54. GallagherJP.Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand. 1989;80(2):114–17.
55. GubbaySS, KahanaE, ZilberNet al. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. J Neurol. 1985;232(5):295–300.
56. FeinsteinA, FeinsteinK, GrayT, O’ConnorP.Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol. 1997;54(9):1116–21.
57. StarksteinSE, MigliorelliR, TesonAet al. Prevalence and clinical correlates of pathological affective display in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1995;59(1):55–60.
58. RobinsonRG.The Clinical Neuropsychiatry of Stroke. 2nd edition. Cambridge: Cambridge University Press; 2006.
59. TrimbleMR, SchmitzB.The Neuropsychiatry of Epilepsy. 2nd edition. Cambridge: Cambridge University Press; 2011.
60. CoffeyCE, McAllisterTW, SilverJM.Guide to Neuropsychiatric Therapeutics. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
61. YudofskySC, HalesRE, American Psychiatric Publishing. The American Psychiatric Publishing Textbook of Neuropsychiatry And Behavioral Neurosciences. 5th edition. Washington, DC: American Psychiatric Publishing; 2008.
62. SilverJM, McAllisterTW, YudofskySC.Textbook of Traumatic Brain Injury. 2nd edition. Arlington, VA: American Psychiatric Publishing; 2011.
63. KrishnamoorthyES, PrinceM, CummingsJL.Dementia: A Global Approach. Cambridge: Cambridge University Press; 2010.
64. LauterbachEC.Psychiatric Management in Neurological Disease. 1st edition. Washington, DC: American Psychiatric Press; 2000.
65. AarslandD, MarshL, SchragA.Neuropsychiatric symptoms in Parkinson's disease. Mov Disord. 2009;24(15):2175–86.
66. JettyPV, CharneyDS, GoddardAW.Neurobiology of generalized anxiety disorder. Psychiatr Clin North Am. 2001;24(1):75–97.
67. MartinEI, ResslerKJ, BinderE, NemeroffCB.The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am. 2009;32(3):549–75.
68. NinanPT, DunlopBW.Neurobiology and etiology of panic disorder. J Clin Psychiatry 2005;66(Suppl. 4):3–7.
69. RaisonCL, CapuronL, MillerAH.Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24–31.
70. KulisevskyJ, Pascual-SedanoB, BarbanojMet al. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: a double-blind study. Mov Disord. 2007;22(1):62–7.
71. ZafonteR, HammondF, DennisonA, ChewE.Pharmacotherapy to enhance arousal: what is known and what is not. Prog Brain Res. 2009;177:293–316.
72. MiyasakiJM, ShannonK, VoonVet al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66(7):996–1002.
73. DoodyRS, StevensJC, BeckCet al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1154–66.
74. American Psychiatric Association. Treatment of Patients with Major Depressive Disorder. Washington, DC: American Psychiatric Publishing; 2011.
75. SinyorM, SchafferA, LevittA.The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry 2010;55(3):126–35.
76. PriceA, RaynerL, Okon-RochaEet al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry 2011;82(8):914–23.
77. SheltonRC.Intracellular mechanisms of antidepressant drug action. Harv Rev Psychiatry 2000;8(4):161–74.
78. TarditoD, PerezJ, TiraboschiEet al. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev. 2006;58(1):115–34.
79. SchmittJA, KruizingaMJ, RiedelWJ.Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol. 2001;15(3):173–9.
80. DubovskySL.Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatry 1994;55(Suppl.):34–44.
81. ZarateCA, Jr, SinghJB, CarlsonPJet al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856–64.
82. PittengerC, CoricV, BanasrMet al. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 2008;22(9):761–86.
83. GuayDR.Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006;4(4):330–46.
84. SaartoT, WiffenPJ.Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4:CD005454.
85. KrymchantowskiAV, SilvaMT, BarbosaJS, AlvesLA.Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache 2002;42(6):510–14.
86. LojJ, SolomonGD.Migraine prophylaxis: who, why, and how. Cleve Clin J Med. 2006;73(9):793–4, 7, 800–1 passim.
87. GerberPE, LyndLD.Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998;32(6):692–8.
88. DubovskySL, ThomasM.Tardive dyskinesia associated with fluoxetine. Psychiatr Serv. 1996;47(9):991–3.
89. American Psychiatric Association. Treatment of Patients with Bipolar Disorder. Washington, DC: American Psychiatric Publishing; 2002. Available from: http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_8.aspx.
90. DerryS, MooreRA.Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 2007;7:40.
91. BauerMS, MitchnerL.What is a “mood stabilizer”? An evidence-based response. Am J Psychiatry 2004;161(1):3–18.
92. CalabreseJR, BowdenCL, SachsGet al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64(9):1013–24.
93. BowdenCL, CalabreseJR, SachsGet al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60(4):392–400.
94. ConwayCR, ChibnallJT, NelsonLAet al. An open-label trial of adjunctive oxcarbazepine for bipolar disorder. J Clin Psychopharmacol. 2006;26(1):95–7.
95. VasudevK, MacritchieK, GeddesJ, WatsonS, YoungA.Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev. 2006;1:CD003384.
96. TuckerP, TrautmanRP, WyattDBet al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68(2):201–6.
97. LindleySE, CarlsonEB, HillK.A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol. 2007;27(6):677–81.
98. KrugerS, SarkarR, PietschR, HasencleverD, BraunigP.Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania – a randomized open-label study. Psychopharmacology (Berlin) 2008;198(2):297–9.
99. PostRM, AltshulerLL, FryeMAet al. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. J Clin Psychiatry 2005;66(3):370–4.
100. WangPW, YangYS, ChandlerRAet al. Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study. J Psychiatr Res. 2008;42(6):451–7.
101. DubovskySL.Calcium channel antagonists as novel agents for manic-depressive disorder. In SchatzbergAF, NemeroffCB, editors. The American Psychiatric Press Textbook of Psychopharmacology. 1st edition. Washington, DC: American Psychiatric Press; 1995, pp. 377–88.
102. PostRM, PazzagliaP, KetterTAet al. Carbamazepine and nimodipine in refractory bipolar illness: efficacy and mechanisms. In HalbreichU, MontgomerySA, editors. Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders. Washington, DC: American Psychiatric Press; 2000, pp. 77–110.
103. WardenDL, GordonB, McAllisterTWet al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma 2006;23(10):1468–501.
104. EvansDL, ByerlyMJ, GreerRA.Secondary mania: diagnosis and treatment. J Clin Psychiatry 1995;56(Suppl. 3):31–7.
105. ColeP, RabassedaX.Quetiapine in bipolar disorder: increasing evidence of efficacy and tolerability. Drugs Today (Barcelona) 2004;40(10):837–52.
106. SerrettiA, De RonchiD, LorenziC, BerardiD.New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem. 2004;11(3):343–58.
107. DanielsJP, FeldeA.Quetiapine treatment for mania secondary to brain injury in 2 patients. J Clin Psychiatry 2008;69(3):497–8.
108. DervauxA, LevasseurM.Risperidone and valproate for mania following stroke. J Neuropsychiatry Clin Neurosci. 2008;20(2):247.
109. GoyalR, SameerM, ChandrasekaranR.Mania secondary to right-sided stroke – responsive to olanzapine. Gen Hosp Psychiatry 2006;28(3):262–3.
110. YehHL, TsaiSJ.Lithium may be useful in the prevention of Alzheimer's disease in individuals at risk of presenile familial Alzheimer's disease. Med Hypotheses 2008;71(6):948–51.
111. KessingLV, SondergardL, FormanJL, AndersenPK.Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008;65(11):1331–5.
112. SassiRB, NicolettiM, BrambillaPet al. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett. 2002;329(2):243–5.
113. TohenM, CalabreseJR, SachsGSet al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163(2):247–56.
114. VietaE, SuppesT, EggensIet al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008;109(3):251–63.
115. ThaseME, MacfaddenW, WeislerRHet al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600–9.
116. BrodtkorbE, MulaM.Optimizing therapy of seizures in adult patients with psychiatric comorbidity. Neurology 2006;67(12 Suppl. 4):S39–44.
117. StrawnJR, KeckPE, Jr, CaroffSN.Neuroleptic malignant syndrome. Am J Psychiatry 2007;164(6):870–6.
118. CroarkinPE, EmslieGJ, MayesTL.Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008;69(7):1157–65.
119. StevensDL.Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42(9):1290–7.
120. RayWA, ChungCP, MurrayKT, HallK, SteinCM.Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–35.
121. ReillyJG, AyisSA, FerrierIN, JonesSJ, ThomasSH.Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2002;180:515–22.
122. PassmoreMJ, GardnerDM, PolakY, RabheruK.Alternatives to atypical antipsychotics for the management of dementia-related agitation. Drugs Aging 2008;25(5):381–98.
123. FriedmanJH.Atypical antipsychotics in the elderly with Parkinson disease and the “black box” warning. Neurology 2006;67(4):564–6.
124. SchneiderLS, DagermanK, InselPS.Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14(3):191–210.
125. KalesHC, ValensteinM, KimHMet al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007;164(10):1568–76; quiz 623.
126. BrooksJO, HoblynJC.Neurocognitive costs and benefits of psychotropic medications in older adults. J Geriatr Psychiatry Neurol. 2007;20(4):199–214.
127. HackettML, YangM, AndersonCS, HorrocksJA, HouseA.Pharmaceutical interventions for emotionalism after stroke. Cochrane Database Syst Rev. 2010;2:CD003690.
128. HouseAO, HackettMI, AndersonCS, HorricksJA.Pharmaceutical interventions for emotionalism after stroke: the Cochrane Stroke Group. Stroke 2004;35(6):E218-E.
129. WortzelHS, AndersonCA, ArciniegasDB.Treatment of pathologic laughing and crying. Curr Treat Options Neurol. 2007;9(5):371–80.
130. DubovskySL.Clinical Guide to Psychotropic Medications. 1st edition. New York, NY: Norton; 2005.
131. SchneiderLS, TariotPN, DagermanKSet al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525–38.
132. SultzerDL, DavisSM, TariotPNet al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008;165(7):844–54.
133. SelbaekG, KirkevoldO, EngedalK.The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes – a 12-month follow-up study. Am J Geriatr Psychiatry 2008;16(7):528–36.
134. BrookeMM, PattersonDR, QuestadKA, CardenasD, Farrel-RobertsL.The treatment of agitation during initial hospitalization after traumatic brain injury. Arch Phys Med Rehabil. 1992;73(10):917–21.
135. YudofskySC.Beta-blockers and depression. The clinician's dilemma. J Am Med Assoc. 1992;267(13):1826–7.
136. PollockBG, MulsantBH, RosenJet al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007;15(11):942–52.
137. DubovskySL, ThomasM.Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction. J Psychosom Res. 1995;39(4):429–44.
138. CantillonM, BrunswickR, MolinaD, BahroM.Buspirone vs haloperidol – a double-blind trial for agitation in a nursing home population with Alzheimer's disease. Am J Geriat Psychiatry 1996;4(3):263–7.